Scarica l'app Stockscreener
16.16
1.32%
0.20
Tourmaline Bio Inc Borsa (TRML) Ultime notizie
Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Bought by California State Teachers Retirement System - Defense World
Cantor Fitzgerald Weighs in on Tourmaline Bio FY2026 Earnings - Defense World
Two Sigma Investments LP Sells 21,904 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio Releases Updated Corporate Presentation - TipRanks
Tourmaline Bio Elects Directors and Ratifies Auditor - TipRanks
Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Bought by Bank of America Corp DE - Defense World
Nuveen Asset Management LLC Has $1.55 Million Stock Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
BNP Paribas Financial Markets Reduces Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Jane Street Group LLC Cuts Stock Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $291,000 Stake in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Deutsche Bank AG Grows Stock Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of “Buy” from Brokerages - Defense World
BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML) - MSN
H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results - Insider Monkey
H.C. Wainwright maintains $50 target on Tourmaline Bio stock By Investing.com - Investing.com India
H.C. Wainwright maintains $50 target on Tourmaline Bio stock - Investing.com
Millennium Management LLC Has $7.40 Million Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Leerink Partnrs Comments on Tourmaline Bio FY2026 Earnings - Defense World
Tourmaline Bio Shares Drop After Phase 2 Results for Obesity Drug Pacibekitug Fail to Meet Analyst Expectations - geneonline.com
Tourmaline Bio, Inc. (NASDAQ:TRML) Stock Position Lifted by Northern Trust Corp - Defense World
BMO maintains $35 target on Tourmaline Bio, sees overreaction - Investing.com Australia
Tourmaline Bio stock holds $63 target post-Ph2 data By Investing.com - Investing.com Nigeria
BMO maintains $35 target on Tourmaline Bio, sees overreaction By Investing.com - Investing.com Nigeria
Tourmaline Bio stock holds $63 target post-Ph2 data - Investing.com
Tourmaline shares waver as investors mull mid-stage pacibekitug data - The Pharma Letter
In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD - insights.citeline.com
Tourmaline Bio (TRML) Shares Drop After Trial Data Release - GuruFocus
Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition - Seeking Alpha
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings - Benzinga
Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff - BioPharma Dive
Buy Rating for Tourmaline Bio Driven by Promising Clinical Results and Market Potential - TipRanks
Tourmaline Bio's heart drug cuts inflammation as it seeks to compete with Novo, CSL's assets - Endpoints News
Tourmaline Bio Says Pacibekitug Trial Showed 'Deep, Durable Reduction' in High-Sensitivity C-Reactive Protein - marketscreener.com
Transcript : Tourmaline Bio, Inc.Special Call - marketscreener.com
Tourmaline Bio Announces Positive Phase 2 Trial Results - TipRanks
Tourmaline Bio Reports Positive Topline Data From Phase 2 TRANQUILITY Study - Nasdaq
Tourmaline Bio stock slips after trial data (TRML:NASDAQ) - Seeking Alpha
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial - marketscreener.com
Tourmaline shares edge lower despite phase 2 trial results - Investing.com Australia
Tourmaline Bio (TRML) Reports Encouraging Results from Phase 2 C - GuruFocus
Tourmaline Bio Announces Positive Topline Results from the - GlobeNewswire
Breakthrough Clinical Trial: New Quarterly Drug Cuts Heart Disease Risk Marker by 85% in Kidney Disease Patients - Stock Titan
Tourmaline shares edge lower despite phase 2 trial results By Investing.com - Investing.com South Africa
Tourmaline Bio to reveal Phase 2 trial results tomorrow By Investing.com - Investing.com South Africa
Tourmaline Bio to reveal Phase 2 trial results tomorrow - Investing.com Australia
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 - The Manila Times
Tourmaline Bio to Host Conference Call on Phase 2 TRANQUILITY Trial Results for Pacibekitug in Chronic Kidney Disease - Nasdaq
Major Phase 2 Trial Results Coming: Tourmaline Bio's Novel CKD Drug Could Transform Patient Care - Stock Titan
1.80%
0.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):